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license (http://creativecommons.org/Summary Bone morphogenetic proteins (BMPs) are a group of signalling molecules that
belong to the transforming growth factor-b superfamily of proteins. Initially identified for their
ability to induce bone formation, recent advances in the understanding of cellular and molec-
ular mechanisms regarding BMPs have led to the use of the growth factor to accelerate bone
healing. Recent clinical trials have demonstrated that BMPs, BMP-7 in particular, may present
an alternative line of treatment other than the gold standard, autogenous bone grafting, in the
treatment of fracture nonunion. We performed a literature search in September 2014 of
PubMed and Embase using search terms, including “bone morphogenetic proteins”, “BMP-7”,
“non-union”, “fracture healing” and “cost-effectiveness”, reviewing the efficacy, safety,
and cost of treatment of nonunions with BMP-7. The authors further canvassed the reference
lists of selected articles and used online search tools, such as Google Scholar. BMP-7 uses both
the canonical and noncanonical signalling pathways. The treatment of fracture nonunion with
recombinant human BMP-7 (rhBMP-7) has a comparable efficacy with that of autogenous bone
grafting with an average union rate of 87% compared with 93% for bone grafting. Furthermore,
fewer complications have been described with the use of rhBMP-7 compared with traditional
bone grafting. We describe the signalling pathways that BMP-7 uses to exert its effect on bone.
In nonunions, rhBMP-7 has been shown to have a similar efficacy to bone grafting with fewer
complications.
Copyright ª 2015, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open ac-
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).edicine, University of Queensland, 6 Seventh Avenue, Windsor, 4030, Brisbane, Queensland, Australia.
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hors. Published by Elsevier (Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND
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In 1965, Urist [1] demonstrated that the demineralised,
lyophilised segments of a bone were capable of a new bone
formation when implanted into ectopic sites in rabbits.
Subsequent research in the 1980s led to the dissociation of
the bone-inducing component from the demineralised bone
matrix into a soluble component using acid and chaotropic
agents [2]. Following a biochemical analysis of the extract,
proteins were cloned and tested for in vivo activity. An
analysis of these clones indicated that the bone-inductive
extract consisted of a highly conserved family of related
proteins, named bone morphogenetic proteins (BMPs) [3].
This family consists of dimeric molecules belonging to the
transforming growth factor-b (TGF-b) superfamily, contain-
ing a highly conserved seven-cysteine TGF-b domain in their
C-termini [4]. To date, approximately 20 BMP family mem-
bers have been identified and characterised [5] (Table 1).
Further evidence that BMPs were responsible for the
bone-inductive activity in bone matrix was found in the
recombinant expression of each of these proteins. By the
use of molecular-biology techniques and sequence infor-
mation from the bovine molecular clones, the human ho-
mologues of each BMP coding sequence were obtained.
Mammalian cells were engineered to express the protein by
inserting a vector encoding human BMP into the mammalian
cell host of choice, resulting in the production of a single
BMP molecule on amplification [6]. Early studies utilising
this method focused on the function of BMP-7 [6]. Re-
searchers were able to demonstrate that implantation of
recombinant human BMP-7 (rhBMP-7) was capable of
inducing a new bone formation. Numerous subsequent
studies have proven the potency of rhBMP-7 using critical-
size long-bone defects. These defects are defined by not
being able to heal without therapeutic intervention and the
application of exogenous stimuli. The implantation of BMP-
7 into surgically created critical-size diaphyseal segmental
defects led to the regeneration of a new bone that was fullyTable 1 Bone morphogenetic proteins with musculoskel-
etal function (modified from (5)).
Identification Description
BMP-2 Bone and cartilage morphogenesis,
osteoinduction, osteoblast differentiation,
apoptosis
BMP-3 Negative regulator of bone morphogenesis
BMP-3b Negative regulator of bone morphogenesis
BMP-4 Cartilage, teeth and bone morphogenesis
BMP-5 Limb development, cartilage and bone
morphogenesis
BMP-6 Osteoblast differentiation, chondrogenesis
BMP-7 Cartilage and bone morphogenesis
BMP-8 Bone and cartilage morphogenesis
BMP-9 Bone morphogenesis
BMP-11 Axial-skeleton patterning
BMP-12 Ligament and tendon development
BMP-13 Cartilage development
BMP-14 Chondrogenesis, angiogenesis
BMP Z bone morphogenetic protein.functional both biologically and biomechanically [7,8]. The
therapeutic potential of BMP-7 has been widely studied in
both animal studies and human clinical trials [9,10]. Given
the potential of BMPs in orthopaedic applications, this has
resulted in the commercialisation of rhBMP-7.
Due to the supportive preclinical and clinical data, and
approval from the Food and Drug Administration, rhBMP-7
(also known as osteogenic protein-1) is now commercially
available. BMP-7 is now widely used in a variety of complex
orthopaedic conditions either as an adjunct or as an
alternative. It is particularly useful in the nonunion of bone
as an alternative to conventional autogenous bone grafting
(ABG), where the use of ABG alone is not feasible and/or
other alternative treatments have failed. Recent studies
have shown the efficacy of rhBMP-7 in inducing bone for-
mation in nonunions to be equivalent to ABG. However, the
avoidance of considerable issues, including donor-site
morbidity, volume constraints, and infection commonly
associated with ABG, has made rhBMP-7 an attractive
alternative in the stimulation of bone formation [10,11].
The aim of this review is to discuss recent advances in the
molecular mechanism of BMP-7, as well as clinical studies
regarding the efficacy of rhBMP-7, in treating fracture
nonunion.
Methods
A literature search was performed (September 2014) of
PubMed and Embase using various combinations of the
keyword terms “bone morphogenetic protein”, “BMP”,
“BMP-7”, “non-union”, “cost-effectiveness” and “signal-
ling”, and their associated synonyms. The inclusion criteria
were papers written in English, peer-reviewed journals,
randomised controlled trials, and prospective and retro-
spective case series. The exclusion criteria were abstracts,
case reports, and reviews. For the “signalling” and “com-
plications” sections, reviews were included. The authors
further searched the reference lists of selected articles and
online search engines, such as Google Scholar.
BMP signalling
The BMP family belongs to the TGF-b superfamily of growth
factors, which are involved in vast cellular processes of
fundamental importance. For example, TGF-b has been
demonstrated to be central to embryogenesis in mammals,
controlling the formation of neural tube, limbs, cartilage,
and bone [12,13]. BMPs comprise a large group of phylo-
genetically conserved growth factors of which 20 members
have been identified. In bone, BMPs are produced by
osteoprogenitor cells, osteoblasts, chondrocytes, and
platelets [14]. BMPs are potent osteoblast-differentiation
factors, inducing the differentiation of multipotent
mesenchymal cells into both osteochondrogenic lineage
cells and osteoblast precursor cells [15,16]. The molecular
basis of their action has been the subject of intensive
research in recent years, leading to a growing under-
standing of their fundamental action at a cellular level.
Initially, all BMPs are synthesised as precursor proteins with
an N-terminal signal peptide, a prodomain for folding and
secretion, and a C-terminal mature peptide. Precursors are
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N- and C-terminal fragments. The C-terminal mature frag-
ment is capable of binding to its receptor [17]. BMPs can
signal through both canonical and noncanonical pathways.
With regard to the canonical pathway, BMPs have been
demonstrated to initiate the signal-transduction cascade
by binding to cell surface receptors acting as a ligand,
and forming a complex that comprises two dimers of type
I (BMPR-I) and type II (BMPR-II) serine/threonine kinase
receptors (Figure 1) [14,18]. Six different receptors were
identified to bind BMPs. Type I receptors include activin
receptor type Ia (ActRIa), BMP receptor type Ia (BRIa) and
BMP receptor type Ib. They form hetero-tetrameric com-
plexes with the following type II receptors: BMP receptor
type II (BRII), Activin receptors type IIA and IIB (ActRIIA
and ActRIIB) (19). In the case of BMP-7, the growth factor
has been proposed to first bind to the type II receptor
followed by recruitment and phosphorylation of the type I
receptor [19]. Subsequently, the activated type I re-
ceptors phosphorylate intracellular effector proteins,
receptor-regulated Smads, activating Smad1, Smad5, and
Smad8 (Smad1/5/8) [20]. The activation of receptor-
regulated Smads then allows the formation of a complex
with comediator Smad, Smad4, which translocates to the
nucleus, functioning as a transcription factor and regu-
lating gene expression. In addition to the Smad-
dependent activation, other BMP signalling pathways
have also been identified and shown to mediate the
osteoinductive signals of BMPs. These include the Smad-
independent p38 mitogen-activated protein-kinaseFigure 1 BMPs signal via the Smad-dependent pathway (canonic
BMPs bind type I or type II receptors, forming a heterotetrameric
Smads (Smad1/5/8). Phosphorylated R-Smads associate with co-
regulate gene expression. Non-canonical pathways, including mitog
expression (modified from (17)).pathway and phosphatidylinositol 3-kinase/protein kinase
b pathway (noncanonical pathway) [21].
The postulated convergence of the two pathways in
relation to osteogenesis occurs at the regulation of various
transcription factors, in particular, at the runt-related
transcription factor 2 and Osterix genes, key transcription
factors in osteoblast differentiation [22,23]. The deletion
of Osterix and runt-related transcription factor 2 has been
shown to cause the loss of ossification [24]. This mechanism
initiates the signal cascade leading to bone differentiation
(Figure 2). At a cellular level, BMPs diffuse through a con-
centration gradient acting as ligands for receptors present
on plasma membranes of various cells, such as osteoblasts
as well as mesenchymal stem cells, inducing differentiation
and proliferation following a defined spatial arrangement
[4]. Ultimately, cells are stimulated to differentiate into
chondrocytes within 5e7 days of application of BMP. Upon
capillary invasion, the chondrocytes become calcified and
hypertrophied, and are subsequently replaced by new
formed bone within 9e12 days. The mineralised bone un-
dergoes remodelling and becomes occupied by ossicles fil-
led with functional bone-marrow elements by 14e21 days.
This process of bone formation is equivalent to that which
occurs physiologically; therefore, BMPs appear to play a
central regulatory role in ossification and bone healing. This
understanding, as well as the preclinical research, indicates
the potential of BMPs as a biological enhancer of bone
formation, particularly in cases of nonunion, where this
may not be occurring naturally, and has led to further
research in a clinical setting.al) or various non-Smad dependent pathways. In the canonical
complex. Receptor activation allows the phosphorylation of R-
Smad (Smad 4). The complex translocates to the nucleus to
en-actviated protein kinase, can also lead to regulation of gene
Figure 2 Image illustrating the molecular mechanism by
which bone morphogenetic proteins stimulate bone formation.
Initially, mesenchymal stem cells are stimulated to proceed
down the osteogenic lineage. Stimulation occurs due to bone-
morphogenetic-protein activity, leading to increased expres-
sion of runt-related transcription factor 2 and Osterix, neces-
sary for osteoblast differentiation. BMPZ bone morphogenetic
protein; Osx Z Osterix; Runx2 Z runt-related transcription
factor 2.
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Over the past decade, there have been several studies
regarding the use of rhBMP-7 in the setting of fracture
healing. Nonunion can occur following long-bone fracture,
with a prevalence estimated to be approximately 10% of all
fractures, increasing to 50% for open tibial fractures [25,26].
Nonunion is defined as the absence of bone union following
a fracture that requires additional treatment before healing
can occur (>9 months), characterised by sclerotic fracture
edges with sealing of medullary canals often being
described as pseudarthrosis (false joint) [27]. Nonunions are
further divided into hypertrophic, normotrophic, and atro-
phic dependent on the degree of callus formation. The
surgical treatment for all types may involve the removal of
ineffective or infected hardware, bone stabilisation, and
eradication of infection if present [28]. In atrophic non-
unions, characterised by the absence of callus and atrophic
bone ends with deficient vascularity, further debridement
of necrotic tissue with opposition of viable and vascular
bone fragments is necessary. In addition, biological stimu-
lation is required, as nonunion is incapable of a sufficient
biological reaction. Autogenous cancellous bone grafting
remains the gold-standard method for inducing union at the
fracture site. Bone matrix represents a natural reservoir
able to deliver various proteins and growth factors in sig-
nificant quantities at the fracture site, including collagen-I,
insulin-like growth factor-1, TGF-b, acidic fibroblast growthfactor, vascular endothelial growth factor, and platelet-
derived growth factor [29]. Bone matrix is therefore har-
vested from donor sites, such as the iliac crest of the pa-
tient, and is used as a stimulant to induce bone formation at
the site of nonunion. However, the limited availability of
bone suitable for grafting, as well as the considerable
morbidity and complications associated with grafting
[30e32], have led to the development of alternative bio-
logically stimulating agents, such as rhBMP-7.
Several randomised controlled trials and cohort studies
(Table 2) have been published with regard to fracture
nonunion treatment [10,33e37]. Friedlaender et al [35]
published a prospective randomised controlled trial
comparing the treatment of tibial fracture nonunions with
rhBMP-7 and ABG. One hundred and twenty-two patients
were enrolled in the multicentre trial, and each patient
was treated by insertion of an intramedullary rod, accom-
panied by either rhBMP-7 in a type I collagen carrier
(3.5 mg) or by bone autograft. Follow up, 9 months after
the operative procedures, demonstrated that 81% of non-
unions treated with rhBMP-7 had united, compared with
85% of those receiving autogenous bone. At 2 years follow
up, there was no significant difference in the union rate
between the two groups, demonstrating a comparable ef-
ficacy between the two treatment groups. Friedlaender
et al [35] provided level 1 evidence that rhBMP-7 is as
effective as ABG in the treatment of tibial nonunion when
used with intramedullary rod fixation.
More recently, Kanakaris et al [10] conducted an
observational study describing the management of femoral
fracture nonunions using rhBMP-7 in six different European
university centres over a period of 5 years. The study
included 30 patients that had undergone a median of one
revision operation before rhBMP-7 application, and were
followed up for a median of 24 months. In 23 cases, the
application of rhBMP-7 was combined with a revision of
fixation, and 12 cases also included autograft. The BMP-
treated patients were treated with 3.5 mg rhBMP-7.
Nonunion healing occurred in 86.7% of the cases in a me-
dian period of 6 months, which is comparable with the
conventional gold-standard treatment with ABG [11]. No
systemic allergic reactions or adverse effects were noted
following the application of rhBMP-7, and no complications
related to the bone substitute were observed. Thus, this
study showed that BMP-7 is as effective as ABG for femoral
fracture nonunions.
A retrospective study carried out in the UK by Gian-
noudis and Tzioupis [36] reported on 395 patients affected
by nonunion. A single application of 3.5 mg rhBMP-7 was
used during a concurrent treatment with appropriate sur-
gical stabilisation of the fracture nonunion. The overall
success rate was up to 82%. No systemic complications or
adverse effects from the application of rhBMP-7 were re-
ported. A similar study in Belgium regarding tibial fracture
nonunions observed a union rate of 84.9% in the average of
7.5 months [37].Discussion
The nature of bone induction and regeneration is now
better understood. BMP-7 has demonstrated its ability in a
Figure 3 Graph illustrating the union rate demonstrated in
various studies regarding the efficacy of recombinant human
bone morphogenetic protein-7 in healing fracture nonunions
and the calculated average overall of all reviewed studies.
Table 2 Clinical studies on the application of bone morphogenetic proteins at various anatomical sites with an indication of
nonunion.
Authors Type of study Level of
evidence
No. of
cases
of BMPs
Carrier method
and dose
Indication
(anatomical
site of nonunion)
Union
rates
(%)
Mean
time to
union
(mo)
Reoperation
(%)
Friedlaender
et al 2001 [35]
Prospective
randomised
controlled
(BMP-7 vs. ABG)
II 63 Collagen 3.5 mg Tibial 75e81 9 5
Dimitriou
et al 2005 [33]
Prospective
observational
(BMP-7)
IV 25 Collagen 3.5 mg Tibialefemorale
humeraleforearm
92.3 5.6 12
Kanakaris
et al 2009 [10]
Prospective
observational
(BMP-7)
IV 30 Collagen 3.5 mg Femoral 86.7 6 13
Giannoudis and
Tzioupis
2005 [36]
Retrospective
cohort study
(BMP-7)
IV 395 Collagen 3.5 mg Femoraletibiale
clavicleeanklee
radiusescaphoide
ankleehumeruse
olecranon
82 n/a n/a
Desmyter
et al 2008 [37]
Retrospective
cohort study
IV 62 Collagen 3.5 mg Tibial 84.9 7.5 14
Calori et al
2008 [34]
Prospective
randomised
controlled
(BMP-7 vs. PRP)
III 5 Collagen 3.5 mg Femoral 100 8 6.2
ABG Z autogenous bone grafting; BMP Z bone morphogenetic protein; PRP = platelet-rich plasma.
32 S. Cecchi et al.number of animal models to induce bone formation and
favourably influence the process of bone repair. The growth
factor has been demonstrated to have the capacity to re-
cruit and stimulate differentiation and proliferation of
osteogenic cell populations. The increased interest in
rhBMP-7 as a novel treatment for fracture healing in recent
years has led to clinical trials that show both safety and
efficacy comparable with the current gold standard, ABG. A
series of studies over the past decade have also shown
healing rates for rhBMP-7 between 75% and 100% (Figure 3)
[10,33e37]. ABG has shown a healing rate of 87e100% for
tibial nonunion [11]. These results should be interpreted in
the context of other factors involved in treatment options,
such as indications, contraindications, complication rate,
and economic factors. It is important to recognise the need
to follow established surgical principles, including the
establishment of a bacteriologically clean, viable, and well-
vascularised surgical site with adequate stabilisation of
fracture, perquisites to the success of any osteogenic
stimulus [28].
Treatment with rhBMP-7 shows a lower morbidity and
mortality rate than ABG. Goulet et al [38] studied the
complications seen in the harvesting of ABGs, and found an
incidence of 2.4% for major complications (defined as a
requirement for additional hospitalisation related to the
wound site) and 21.8% for minor complications (defined as
complications at the wound site requiring additional med-
ical attention, but no further hospitalisation). Some pa-
tients (37.9%) reported pain at the graft harvest site 6
months postoperatively. The potential to avoid these
complications is an advantage of the rhBMP-7 treatment.Conversely, treatment with rhBMP-7 is associated with
few complications. Kanakaris et al [10] reported that no
adverse effects directly related to the procedure were seen
in their case series. Courvoisier et al [39] completed a
literature review to determine the safety of rhBMP-7 for
use in long-bone nonunion, and were able to recommend
Bone morphogenetic protein-7 33the product for this purpose. The only notable adverse ef-
fect was transient aseptic wound swelling, seen more often
when the BMP is located superficially. Certain immunologic
problems have been reported, with both anticollagen and
anti-rhBMP proteins identified, however, these do not
necessarily or often predict adverse clinical outcomes [40].
Poynton and Lane [40] reported that low-titre immune re-
sponses were recorded in 38% of patients treated with
rhBMP-7, with no associated clinical adverse effects; how-
ever, they did not recommend the repeated use of rhBMP-7
for this reason. The observed immunologic responses have
been demonstrated to be positively correlated with higher
doses of BMP and collagen. Poynton and Lane [40] also
concluded that rhBMP-7 is safe for normal clinical use, with
no systemic or local toxicity, and no organ damage or car-
cinogenicity found. The long-term effects of these low-titre
immune responses need to be investigated for potential
delayed host reactions.
The current typical dosage of BMP-7 is 3.5 mg, and it is
generally administered bound to 1 g of bovine-collagen
granules that act as a scaffold for bone formation (see
Table 2). This produces a concentration of BMP-7 that is
many times above the physiological level. Given that
Shields et al [41] suggest that the complication rate of BMP-
2 usage is dose dependent, it may be possible to further
reduce complication rates by decreasing the amount of
BMP-7 administered. Priddy et al [42] developed a novel
method for delivering BMP-2 in an oxidised alginate
hydrogel, which allowed them to use a lower concentration
of the drug with no loss of efficacy. This constitutes an area
for future research in BMP-7 technology due to the paucity
of data presently.
Another factor that must be considered when discussing a
new treatment option is the overall economic cost to the
patient. The use of rhBMP-7 compares favourablywith ABG in
this regard, in terms of length of hospital stay (8.66e10.66
days) and length of convalescence (5.5e6.9 months) [43].
The total bill for direct medical costs was found to be 6.78%
higher in the rhBMP-7 group than in the ABG group, largely
due to the high cost of the rhBMP-7 itself; however, given the
significant reduction in hospital stay, morbidity and mortal-
ity, and convalescence of the rhBMP-7 group, Dahabreh et al
[43] were able to advocate in favour of the overall economic
benefits of rhBMP-7 treatment. In addition, Garrison et al
[44] concluded from the available evidence that the eco-
nomic benefits of rhBMP-7 are likely to be more pronounced
in serious fractures that would otherwise result in longer
convalescent times.
The use of rhBMP-7 in combination with ABG has been
studied and found to show higher rates of fracture healing
than either method alone. Giannoudis et al [45] applied this
treatment rationale to 45 patients with nonunion of a long
bone and median of two previous operations, and were able
to demonstrate clinical and radiologic healing in 100% of
those patients.Conclusion
When viewed in the wider context of economic and clinical
benefits compared with the existing gold standard, rhBMP-7
appears to be a promising line of treatment that showsparticular potential in the treatment of fractures resistant
to healing. Clinical trials provide evidence to support the
equivalent efficacy of rhBMP-7 and ABG in terms of healing
rates, showing similar results for the two treatment
methods (87% vs. 93%). However, the favourable safety
profile of rhBMP-7, and the obviation of a bone autograft
donor site and its associated morbidity and mortality sup-
port rhBMP-7 as the preferred method of therapeutic
intervention in nonunions. Existing data suggest that
rhBMP-7 should be reserved for more difficult cases,
particularly in cases of recalcitrant nonunions, although
growing clinical experience using this evolving technology
will more than likely see the expansion of clinical applica-
tions of rhBMP-7.Conflicts of interest
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